Rogers, Jennifer, and Don D. Sheriff. Role of estrogen in nitric oxide-and prostaglandin-dependent modulation of vascular conductance during treadmill locomotion in rats. J Appl Physiol 97: 756 -763, 2004; 10.1152/japplphysiol.00115.2004.-Endothelial production of nitric oxide (NO) and prostaglandins (PG) may be greater in females than in males, increasing vasodilatory responses in females. Does sex influence the cardiovascular responses to dynamic exercise through estrogen-dependent modulation of NO and PG vasodilatory pathways? After the administration of hexamethonium, we assessed terminal aortic blood flow (TAQ), mean arterial pressure (MAP), and hindlimb vascular conductance (VC) in four groups of rats (6 males, 5 females, 5 ovariectomized females, and 6 ovariectomized females with chronic estrogen supplementation) during graded mild-intensity treadmill locomotion (5-15 m/min, 0°grade, 2 min). All rats repeated exercise after cyclooxygenase inhibition (indomethacin) and then again after NO synthase inhibition (nitro-L-arginine methyl ester) to examine the roles of NO and PG. Regression analysis was used to determine the influence of sex and plasma 17␤-estradiol on TAQ, MAP, and VC. The analysis revealed that female sex did not influence TAQ but reduced MAP and increased VC at rest and during exercise conditions. Plasma 17␤-estradiol (measured by immunoassay) significantly decreased MAP and increased TAQ and VC, irrespective of sex. Cyclooxygenase inhibition eliminated the significant association between MAP and estrogen, suggesting that estrogenic modulation occurred through PG-dependent processes. In contrast, the significant influence of estrogen on TAQ and VC was eliminated after NO synthase inhibition. On the basis of the overall findings of this study, estrogen influenced the vascular responses to dynamic exercise through PG-and NO-dependent pathways, but this occurred independent of sex. active hyperemia; dynamic exercise; limb blood flow; arterial pressure THE VASCULAR ENDOTHELIUM, consisting of a single layer of cells lining the intimal surfaces of blood vessels, plays a substantial role in the regulation of vascular smooth muscle function and regional vascular tone through the production of numerous vasoactive substances. Estrogen modulates vascular responsiveness to stimuli evoking flow-induced vasodilation, in part through enhanced release of vasodilatory signaling molecules such as nitric oxide (NO), prostacyclin, and endothelial-derived hyperpolarizing factors from the vascular endothelium (9 -11, 17, 20, 26). Endothelial-derived NO and prostacyclin contribute to flow-induced vasodilation (13, 27) and possibly the hyperemic response to dynamic exercise (2, 6, 23).
THE VASCULAR ENDOTHELIUM, consisting of a single layer of cells lining the intimal surfaces of blood vessels, plays a substantial role in the regulation of vascular smooth muscle function and regional vascular tone through the production of numerous vasoactive substances. Estrogen modulates vascular responsiveness to stimuli evoking flow-induced vasodilation, in part through enhanced release of vasodilatory signaling molecules such as nitric oxide (NO), prostacyclin, and endothelial-derived hyperpolarizing factors from the vascular endothelium (9 -11, 17, 20, 26) . Endothelial-derived NO and prostacyclin contribute to flow-induced vasodilation (13, 27) and possibly the hyperemic response to dynamic exercise (2, 6, 23) .
Inhibition of NO synthase, the class of enzymes catalyzing the formation of NO, is characterized by a significant decrease in resting blood flow and vascular conductance (VC), although the magnitude of the rise in blood flow and VC in response to exercise is not affected (14, 18, 21) . Similarly, cyclooxygenase inhibition, which attenuates prostaglandin (PG) production (including endothelially derived prostacyclin), decreases the absolute level of blood flow and VC achieved during exercise (12) . One common limitation to studies examining the contributions of endothelium-induced vasodilation to exercise hyperemia is that the production of only one endothelial vasodilator is inhibited. It is possible that, in the event of NO synthase inhibition, a greater stimulus for endothelial PG production exists and sustains the "normal" hyperemic response to exercise and vice versa. Furthermore, it has been found in isolated skeletal muscle arterioles that sex alters the specific endothelial mediators that elicit flow-induced vasodilation (3, 27) . It is unknown whether sex differences in the relative contributions of NO and PG production or overall vascular tone are present during exercise conditions or whether estrogen modulates vascular responses to dynamic exercise.
Therefore, the purpose of this study was to determine whether estrogen influenced the contributions of NO and PG to the hyperemic response to treadmill locomotion. To test this, we used four groups of rats: males, females, ovariectomized females, and ovariectomized females with chronic estrogen supplementation. Each rat completed an exercise protocol consisting of treadmill locomotion at several speeds (5, 7.5, 10, and 15 m/min). All data were collected after efferent autonomic function was inhibited by hexamethonium. This was done to eliminate potential sex differences in sympathetic function, thereby allowing us to focus on the influence of sex on peripheral vascular factors. Exercise bouts were imposed under control (hexamethonium) conditions, during the time that both autonomic function and cyclooxygenase were inhibited, and during the time that autonomic function, cyclooxygenase, and NO synthase were inhibited. All animals performed exercise under all of these conditions. Although we created four distinct animal groups with the intent of creating varying levels of plasma estradiol (E 2 ) concentrations, neither our hypotheses nor our analysis explicitly focused on comparisons among the individual groups of animals. Rather, we focused on determining the importance of specific factors that are known to vary within each group of animals (e.g., plasma E 2 concentrations) as well as across the groups of animals (e.g., being female, ovary removal). For example, although plasma E 2 concentrations were certainly expected to be high in the 17␤-estradiol-supplemented treatment group and could potentially exert an important influence on vascular function, E 2 concentrations were also expected to vary within the shamoperated female group (and indeed among the male treatment group as well), and our analysis sought to take these factors into account. Our hypotheses are as follows: 1) VC will be positively associated with estrogen status and 2) to the extent that hypothesis 1 is correct, cyclooxygenase inhibition and NO synthase inhibition will decrease VC in proportion to the contribution that each of these vasodilator pathways makes to any estrogen-mediated differences. Thus our approach was twofold. First, we intentionally manipulated plasma E 2 levels, as well as other sex factors, across a wide range. Second, we administered specific inhibitors of vasodilator pathways that are influenced by estrogen and possibly other sex factors to test the extent to which these pathways constitute mechanisms by which sex differences in exercise hyperemia might be expressed.
METHODS

Animals
Four groups of Sprague-Dawley rats were used during the following experimental protocols: sham-operated males (n ϭ 6, 364 -446 g), sham-operated females (n ϭ 5, 258 -284 g), ovariectomized females (n ϭ 5, 264 -302 g), and ovariectomized females with estrogen replacement (n ϭ 6, 218 -274 g). Each animal was familiarized with locomotion on a rodent treadmill (model 1010 Modular Treadmill, Columbus Instruments, Columbus, OH) before undergoing the experimental protocols. All procedures complied with National Institutes of Health guidelines and were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Iowa.
Surgical Preparation
All animals were obtained at 12 wk of age. Each animal underwent either a sham operation or ovariectomy (with or without estrogen replacement) and was allowed a 4-wk recovery period. After the administration of anesthesia (2% isoflurane inhalation), a midline abdominal incision was made during the ovariectomy procedure to locate the uterus and ovaries. The junction between the uterus and each ovary was ligated, followed by ovary excision. The abdominal incision was then closed in layers. Sham-operated rats underwent a similar procedure without removal of the ovaries. In ovariectomized females with estrogen supplementation, a small incision was made in the skin on the neck for insertion of a time-release estrogen pellet (0.72 mg 17␤-estradiol/pellet, 60-day release, Innovative Research of America) then closed and sutured. Buprenorphine (0.03 mg/kg sq) was given postoperatively for control of pain. During the subsequent recovery period, approximately once per week each animal was required to complete short bouts (Ͻ1 min) of treadmill locomotion at various speeds (5-25 m/min) and grades (Ϫ10 -10°). The goal of this protocol was to promote treadmill familiarization without eliciting significant exercise training responses.
Flow probe insertion was adapted from the methods presented for rats by Sheriff and Hakeman (22) . After anesthetization (2% isofluorane inhalation), a midline abdominal incision was made slightly lateral to the original incision to position an ultrasonic transit-time blood flow transducer (model 1.5RB, Transonic, Ithaca, NY) around the terminal portion of the aorta. The probe cable was tunneled subcutaneously to a midscapular exit site. The animal was allowed to recover for 3-5 days or until an acceptable blood flow signal was acquired. Buprenorphine (0.03 mg/kg sq) was given postoperatively for control of pain.
On the day of an experiment, rats were anesthetized (2% isofluorane inhalation) for catheterization (PE-50 tubing) of a carotid artery for subsequent blood pressure measurement and drug induction. Catheter tubing was tunneled subcutaneously to a midscapular exit site, and the incision was closed in layers. One concern with carotid catheterization is that it may elicit baroreceptor-mediated reflex adjustments in cardiovascular control mechanisms. However, hexamethonium bromide (an inhibitor of autonomic neurotransmission) was administered before experimentation, and this would eliminate the efferent actions of baroreflex-mediated changes in autonomic function elicited by carotid catheterization as well as any potential sex differences in baroreflex sensitivity that could influence cardiovascular function (5, 15) . Animals were allowed sufficient recovery before further experimentation, generally 2-4 h.
Experimental Protocols
Before the experimental protocol was begun, the arterial catheter was connected to a pressure transducer (model P10EZ, Ohmeda, Madison, WI), which was then connected to a signal conditioner (model 660, Gould Instrument Systems, Valley View, OH). The flow transducer was connected to a flowmeter (model T106, Transonic). Signals were displayed on a chart recorder (model MT95K2, AstroMed, West Warwick, RI) and written to a fixed disk of a microcomputer with the use of commercially available software (PONEMAH Physiology Platform, P3, Gould Instrument Systems). Data were digitized at 250 Hz. On completion of the setup procedures, the animal was placed on a rodent treadmill.
The main focus of this protocol was to determine whether estrogen modulated the contributions of NO and PG to cardiovascular responses to dynamic exercise. To eliminate the potentially confounding influence of autonomic adjustments in cardiovascular function during exercise, hexamethonium bromide (10 mg/kg body weight) was administered intra-arterially (carotid catheter) a minimum of 10 min before the first exercise bout. A supplemental dose of hexamethonium (5 mg/kg body weight) was given approximately every 60 min. Once baseline measures for terminal aortic blood flow (TAQ) and mean arterial pressure (MAP) were constant after hexamethonium administration, each animal completed four bouts of treadmill locomotion. Each bout consisted of 2 min of treadmill locomotion followed by 3 min of recovery. Individual bouts at 5, 7.5, 10, and 15 m/min (0% grade) were imposed in no regular order. The TAQ response in rats performing treadmill locomotion within this range of work rates is substantially complete within 30 s of the onset of locomotion (23) .
Each animal was then given an intraperitoneal injection of indomethacin (5 mg/kg body wt, in dimethyl sulfoxide) to inhibit cyclooxygenase activity and therefore PG production. The efficacy of this dose in this species has been demonstrated previously (8, 25) . Indomethacin was given before nitro-L-arginine methyl ester (L-NAME) because indomethacin has little effect on VC at rest (25) , whereas L-NAME has large effects (18, 23) ; varying the order of drug administration might alter the results. A minimum of 30 min were allowed until baseline TAQ and MAP were stable. Animals then repeated the exercise protocol (2 min treadmill locomotion at 5, 7.5, 10, and 15 m/min, 0% grade, followed by 3 min recovery after locomotion at each treadmill speed).
To determine whether NO production could account for any residual differences in cardiovascular parameters after the indomethacin trials, each animal received an intra-arterial injection of L-NAME (10 mg/kg body weight) to inhibit NO synthase activity and was allowed a minimum of 10 min for cardiovascular parameters to stabilize. The efficacy of this dose of L-NAME was inferred from the large rise in MAP coupled with the large decrease in TAQ and hindlimb VC (e.g., Fig. 1 ). The exercise protocol was repeated.
Data Analysis
MAP and TAQ values were averaged over 1-s intervals, beginning before the onset of treadmill locomotion until the end of each exercise bout. To normalize the data to account for significant differences in body size for male and female rats, TAQ was expressed per 100 g of estimated hindlimb weight. On the basis of pilot studies in a separate group of rats, hindlimb body weight (weight of all tissue distal to the flow probe) was calculated as one-third of total body weight, and this value was not significantly different for male and female rats (data not shown). Because regional blood flow and systemic arterial pressure change in response to dynamic exercise, VC (which takes into account blood flow for a given perfusion pressure) was derived as an index to quantify adjustments in vascular tone. Hindlimb VC was calculated as the ratio of TAQ to MAP. Each animal's steady-state value for MAP, TAQ, and hindlimb VC was approximated by taking 15-s averages immediately before locomotion onset (baseline) and for the last 15 s of locomotion at each treadmill speed for hexamethonium, indomethacin, and L-NAME trials. On the completion of the entire exercise protocol, ϳ1 ml of whole blood was obtained from each animal for analysis of plasma E 2 concentrations (chemiluminescence immunoassay; pathology laboratory at University of Iowa Health Center).
Statistical Analysis
To assess the overall contribution of the different treatments across the data set as a whole, a regression was done for each of the primary dependent variables (MAP, TAQ, hindlimb VC). Treatment effects were tested statistically by multiple linear regression (24) . Both dummy variables and actual measured variables were used as independent variables to encode treatment effects analogous to a repeatedmeasures ANOVA (24) . Dummy variables were used to encode for sex (0 for males, 1 for females) and whether the animal was ovariectomized (0 for not ovariectomized, 1 for ovariectomized). Also, dummy variables were used to encode for indomethacin treatment (0 for data collected before indomethacin, 1 for data collected after indomethacin) and for L-NAME treatment (0 for data collected before L-NAME, 1 for data collected after L-NAME). The actual quantitative values of plasma E2 and treadmill speed were also entered into the regression. For example, all values of MAP [equal to 22 rats ϫ 8 conditions (4 work rates and each work rate's associated rest value) ϫ 3 drug conditions (hexamethonium alone, hexamethonium ϩ indomethacin, hexamethonium ϩ indomethacin ϩ L-NAME)], minus one rest and one 15 m/min value for one estrogen-supplemented ovariectomized rat after administration of both indomethacin and L-NAME (equal to 526 values), were entered into a single regression with dummy variables encoding sex, ovariectomy, indomethacin treatment, L-NAME treatment, and the actual measured values of plasma E2 and work rate. This was repeated for analysis of TAQ and hindlimb VC. Significance was accepted at P Ͻ 0.05.
It must be remembered that there is an important distinction for the apparent "strength" of a treatment effect (i.e., the numeric value of the regression coefficient for a particular treatment) between a dummy variable and an actual measured variable. For a dummy variable having a value of unity, all of the treatment effect is "lumped" into the numeric value of the regression coefficient. For example, if the regression coefficient for being female were Ϫ7 mmHg, then being female is associated with a 7-mmHg reduction in MAP. On the other hand, for actual measured variables, the strength of the treatment effect (i.e., the numeric value of the regression coefficient) reflects the strength of the treatment per unit of the measured variable. For A, D, and G) ; HEXϩINDO, hexamethonium ϩ indomethacin trials (B, E, and H); HEXϩINDOϩL-NAME, hexamethonium ϩ indomethacin ϩ nitro-L-arginine methyl ester (L-NAME) trials (C, F, and I) .
example, if the numeric value of the regression coefficient for E2 were Ϫ0.07 mmHg ⅐ pg Ϫ1 ⅐ ml Ϫ1 , then the overall strength of the E2 treatment when plasma E2 concentrations equals 100 pg/ml would be Ϫ7 mmHg.
RESULTS
Descriptive data for each group of animals can be found in Table 1 . The group mean responses of MAP, TAQ, and hindlimb VC across drug treatment conditions are presented in Fig. 1 (for 
Treatment Effects Across the Data Set as a Whole
MAP. The regression coefficients for the treatment effects for the data set as a whole are presented in Table 2 along with their associated P values. For MAP, all of the independent variables produced statistically significant treatment effects ( Table 2 ). For the treatment effects encoded by dummy variables, L-NAME treatment was associated with the largest effect on MAP (ϩ34.2 mmHg; P Ͻ 0.01). Ovariectomy raised MAP by 13.2 mmHg (P Ͻ 0.01) and indomethacin treatment raised MAP by 6.1 mmHg (P Ͻ 0.01). Conversely, the coefficient for the female dummy variable was Ϫ6.9 mmHg, indicating that being female lowered MAP by 6.9 mmHg (P Ͻ 0.01). There was also a significant treatment effect for E 2 (Ϫ0.05 mmHg⅐pg Ϫ1 ⅐ml Ϫ1 ; P Ͻ 0.01). On the basis of the directionally opposite MAP response to exercise before and after L-NAME, (e.g., Fig. 1, A and B vs. C) , a final dummy variable, equal to the product of the dummy variable encoding L-NAME and the actual measured variable reflecting work rate, was entered into the regression to test statistically for the apparent interaction of these two variables. Both work rate and the interaction dummy variable achieved statistical significance. The regression coefficient for work rate was ϩ0.25 mmHg⅐m Ϫ1 ⅐min Ϫ1 (P Ͻ 0.01), indicating that MAP tended to increase by 2.5 mmHg for each 10 m/min increase in treadmill speed in Fig. 1, A and B . The regression coefficient for the dummy variable encoding the interaction between L-NAME and work rate was Ϫ1.1 mmHg⅐m Ϫ1 ⅐min Ϫ1 (P Ͻ 0.01), indicating that MAP tended to fall by 11 mmHg for each 10 m/min increase in treadmill speed (Fig. 1C) .
Hindlimb TAQ. For TAQ, all of the independent variables except the dummy variable encoding female sex were associated with statistically significant treatment effects. For the treatment effects encoded by dummy variables, L-NAME treatment was again associated with the largest effect (Ϫ6.1 ml⅐min Ϫ1 ⅐100 g
Ϫ1
; P Ͻ 0.01). Ovariectomy reduced TAQ by 1.4 ml⅐min Ϫ1 ⅐100 g Ϫ1 (P Ͻ 0.05) and indomethacin treatment reduced TAQ by 1.3 ml⅐min Ϫ1 ⅐100 g Ϫ1 (P Ͻ 0.05). There were also significant treatment effects for E 2 and work rate (both P Ͻ 0.01; Table 2 ).
Hindlimb VC. For hindlimb VC, all of the independent variables were associated with statistically significant treatment effects. For the treatment effects encoded by dummy variables, L-NAME treatment was yet again associated with the largest effect [Ϫ0.0634 ml⅐min Ϫ1 ⅐100 g Ϫ1 ⅐mmHg Ϫ1 (conductance units); P Ͻ 0.01]. Ovariectomy reduced hindlimb VC by 0.0237 conductance unit (P Ͻ 0.01), and indomethacin reduced hindlimb VC by 0.0160 conductance unit (P Ͻ 0.01). Conversely, the coefficient for the dummy variable encoding female sex was ϩ0.0112, indicating that being female raised hindlimb VC by 0.0112 conductance units (P Ͻ 0.05). There were also significant treatment effects (both P Ͻ 0.01) for E 2 (ϩ0.0003 conductance unit⅐pg Ϫ1 ⅐ml Ϫ1 ) and work rate (ϩ0.0080 conductance unit⅐m Ϫ1 ⅐min Ϫ1 ).
Individual Drug Treatment Effects
MAP. By and large, the pattern of the effects of the four treatments on MAP seen across the data set as a whole persisted across each drug condition individually. For example, the strength of the tendency of ovariectomy to increase MAP was similar under each drug condition individually (ϩ13.7, ϩ13.2, and ϩ12.6 mmHg for hexamethonium, indomethacin, and L-NAME, respectively, all P Ͻ 0.001; Table 3 ). Similarly, female sex was associated with an ϳ7 mmHg reduction in MAP across drug conditions (all P Ͻ 0.05; Table 4 ). Notably, the strength of the estrogen treatment effect on MAP seen during hexamethonium alone (Ϫ0.06 mmHg⅐pg Ϫ1 ⅐ml Ϫ1 ; P Ͻ 0.01) was reduced by one-third after administration of indomethacin (to Ϫ0.04 mmHg⅐pg Ϫ1 ⅐ml Ϫ1 ), and E 2 no longer exerted a statistically significant effect (P ϭ 0.09). L-NAME Tables 3 and 5) , and this effect persisted after administration of indomethacin (ϩ0.04 ml Ϫ1 ⅐min Ϫ1 ⅐pg Ϫ1 ⅐ml Ϫ1 ; P Ͻ 0.05). L-NAME administration eliminated the association between plasma E 2 and TAQ (ϩ0.008 ml Ϫ1 ⅐min Ϫ1 ⅐pg Ϫ1 ⅐ml Ϫ1 P ϭ 0.27). On the basis of Fig. 1D , we tested whether the E 2 -supplemented rats had a higher TAQ than the other rats across work rates and found this to be true (P Ͻ 0.05). This difference was eliminated by administration of indomethacin (P ϭ 0.24). Ovariectomy tended to reduce TAQ under each drug alone as it did for the data set as a whole, but these effects did not achieve statistical significance (Table 3) . Female sex exerted little influence on TAQ. As expected, work rate was associated with significant effects on TAQ across drug conditions (Table 3) .
Hindlimb VC. Estrogen was associated with a statistically significant effect on hindlimb VC during hexamethonium alone (ϩ0.0004 conductance unit⅐pg Ϫ1 ⅐ml Ϫ1 ; P Ͻ 0.001), and this effect persisted after administration of indomethacin (ϩ0.0003 unit⅐pg Ϫ1 ⅐ml Ϫ1 ; P Ͻ 0.01). L-NAME administration eliminated the association between E 2 and hindlimb VC (P ϭ 0.18). The effect of ovariectomy on hindlimb VC seen across the data set as a whole persisted across the drug conditions individually (Tables 3 and 6 ). Female sex tended to increase hindlimb VC under each drug alone as it did for the data set as a whole, but these effects did not achieve statistical significance (Table 3) . As expected, work rate was associated with significant effects on hindlimb VC across drug conditions (Table 3) .
Finally, as a more explicit test of our hypotheses, we sought to test whether the extent to which indomethacin reduced the change in the increase in hindlimb VC in response to exercise was related to estrogen status. We found a highly significant Based on data from 6 male, 5 female, 5 ovariectomized female, and 6 ovariectomized estrogen-supplemented rats. Hex, hexamethonium.
Table 4. MAP responses to treadmill locomotion at various work rates in rats
Hex Indo
Values are means Ϯ SE given in mmHg. M, n ϭ 6; F, n ϭ 5; OVX, n ϭ 5; and OVX ϩ E, n ϭ 6. Values are as means Ϯ SE given in ml ⅐ min Ϫ1 ⅐ 100 g Ϫ1 treatment effect, indicating that the greater the plasma E 2 , the greater the reduction in the change in hindlimb VC after indomethacin (P Ͻ 0.001).
DISCUSSION
When the treatment effects for the group data are taken as a whole, a general pattern emerged. Being female was significantly associated with reduced MAP and increased hindlimb VC. Ovary removal (which reduces circulating E 2 and progestins) was associated with reciprocal effects, namely increased MAP and decreased hindlimb VC. Plasma E 2 , either endogenously produced or as a result of the E 2 replacement intervention, partially accounted for the "female" phenotype by reducing MAP and increasing hindlimb VC. Therefore, it appears likely that the differences in vascular regulation (MAP, hindlimb VC) for male and female rats seen across all work rates (0 -15 m/min) are at least partially attributed to estrogenic effects on the vasculature.
Endothelial-derived NO and prostacyclin are the primary intermediaries of flow-induced vasodilation in isolated skeletal muscle arterioles, because NO synthase inhibition and cyclooxygenase inhibition each attenuate the vasodilatory responses to increased luminal flow by ϳ40 -50% in male and female ovariectomized rats (13, 27) . However, recent studies suggest that the relative contributions of NO and prostacyclin to flowinduced vasodilatory responses may exhibit sex specificity because, although the combination of NO synthase and cyclooxygenase inhibition in female and in estrogen-supplemented ovariectomized rats attenuated (by ϳ50%), the vasodilatory response to increased luminal flow in isolated vessels from these animals, the remainder of the vasodilatory response was abolished after subsequent inhibition of endothelial-derived hyperpolarizing factors (9, 27) . Therefore, it has been proposed that estrogen may influence the specific endothelial mediator used to elicit flow-induced vasodilation (7, 10 19) , although it is not known whether this influences cardiovascular regulation during exercise conditions.
To determine whether the estrogenic influences on vascular regulation are mediated through PG and/or NO, we examined the vascular responses to dynamic exercise after different drug treatments (indomethacin, L-NAME) to inhibit PG and NO production. We employed treadmill locomotion, and, of course, different results might be found for other modes of exercise. During these trials, the autonomic nervous system was inhibited to eliminate compensatory changes in autonomic function secondary to drug administration (hexamethonium trials). In general, the influence that each independent variable exerted on the data set as whole tended to be maintained during the hexamethonium trials. Namely, being female and plasma E 2 maintained their significant associations with the reduction in MAP. In addition, plasma E 2 was associated with increased TAQ and hindlimb VC during hexamethonium trials, although the associations between being female and increased TAQ and VC were no longer significant. These findings indicate that, in the absence of autonomic neural inputs, estrogen significantly modulates vascular regulation independent of female sex.
Next, the influence of PG production on vascular regulation was inferred from trials in which cyclooxygenase was inhibited (indomethacin trials). After indomethacin administration, plasma E 2 continued to modulate (increase) TAQ and hindlimb VC, although plasma E 2 was no longer significantly associated with effects on MAP. Similar to the hexamethonium trials, being female did not influence TAQ or hindlimb VC during the indomethacin trials. Female sex, however, continued to be associated with reductions in MAP. It appears that the influence of E 2 on MAP is at least partially dependent on PG production, because cyclooxygenase inhibition eliminated the significant association between E 2 and MAP. In contrast, the strength (regression coefficient) of the association between E 2 and TAQ (and hindlimb VC) was reduced after cyclooxygenase inhibition but not eliminated. The observed increase in TAQ and hindlimb VC associated with E 2 is therefore not likely to be solely mediated through enhanced PG production. Furthermore, these results suggest that there is a reduction in MAP in females that is produced by some factor(s) in addition to the influence exerted by the ovaries and by estrogen. It was also interesting to note that being female was consistently associated with a reduction in MAP across all drug treatments, indicating that the unidentified factor(s) that lowers MAP operates in a manner independent of autonomic function, NO synthase, or cyclooxygenase.
To determine whether E 2 modulates the vascular responses remaining after cyclooxygenase inhibition through NO-dependent processes in the present study, L-NAME was administered to inhibit NO production. After L-NAME, the positive associations between plasma E 2 and hindlimb TAQ and VC were eliminated. E 2 , therefore, appeared to modulate TAQ and VC through NO-dependent pathways. In contrast, female sex was not significantly associated with TAQ or hindlimb VC under any drug condition (hexamethonium, indomethacin, L-NAME). Values are means Ϯ SE given in ml ⅐ min Ϫ1 ⅐ 100 g Ϫ1 ⅐ mmHg Ϫ1 . M, n ϭ 6; F, n ϭ 5; OVX, n ϭ 5; and OVX ϩ E, n ϭ 6.
We found that TAQ was not modulated by female sex. Dynamic exercise can provide a substantial challenge to vascular regulation and may recruit numerous vascular regulatory mechanisms, dependent on exercise intensity, to sustain adequate O 2 delivery. Therefore, under identical exercise conditions, it is not surprising that hindlimb TAQ values for males and females do not differ because overall cardiovascular regulation works to ensure that muscle blood flow is precisely matched with muscle metabolism.
Not surprisingly, work rate significantly influenced the vascular responses elicited during treadmill locomotion. Significant associations were evident between work rate and both TAQ and hindlimb VC after each drug treatment, indicating that factors other than PG or NO also determine vascular responses to changes in work rate. It is important to note, however, that work rate elicited differential responses in MAP according to drug treatment. During hexamethonium and indomethacin trials, no significant associations between work rate and MAP were indicated. On the basis of the regression coefficients, however, work rate tended to elicit (nonsignificant) increases in MAP after hexamethonium and indomethacin. NO synthase inhibition, however, characteristically increases arterial pressure at rest. The typical response to exercise after NO synthase inhibition, therefore, is a decrease in MAP, and this is indeed what we found. Work rate was negatively correlated with MAP during NO synthase inhibition (i.e., increases in work rate brought about significant decreases in MAP).
Plasma E 2 in female rats varies dramatically over a 4-day estrus cycle, typically ranging from 17 pg/ml during the estrus (low estrogen) phase to 88 pg/ml in the proestrus (high estrogen) phase (4) . Plasma E 2 concentrations for male, female, and ovariectomized rats in the present study were similar to the estrus phase of the estrus cycle. Plasma E 2 concentrations for sham-operated females ranged from 13 to 21 pg/ml. Although the ovariectomized rats (with or without E 2 supplementation) demonstrated the expected changes in plasma E 2 concentrations, the sham-operated females did not display variability in plasma E 2 that would be expected during different phases of the estrus cycle, perhaps due to the timing of blood sample procurement (at the end of the experimental protocol) or recent surgical procedures (flow probe insertion) that may have impacted the estrus cycle. The estrogen-supplemented female rats exhibited plasma E 2 concentrations greater than expected for the proestrus phase of the estrus cycle, as well as greater uterine weights despite smaller body sizes, supporting the assumption that estrogen provided significant treatment effects within this treatment group. Plasma E 2 concentrations for the male rats were slightly greater than in sham-operated and ovariectomized female rats, as seen by others (1, 16) Conclusions. The primary purpose of this study was to determine whether estrogenic effects on NO and PG production contribute to differences in the vascular responses to treadmill locomotion for male and female rats. Our principle finding was that across all conditions, female sex was associated with reduced MAP and greater VC. Ovary removal reversed this pattern, and estrogen replacement restored the apparent female phenotype with respect to MAP and VC. Female sex, however, did not exert a significant effect on hindlimb TAQ. Further analysis revealed that plasma E 2 modulated MAP, hindlimb TAQ, and VC across the data set as a whole. Furthermore, the estrogenic influences over MAP were eliminated after cyclooxygenase inhibition, suggesting estrogen modulated MAP in part through PG-dependent processes. In contrast, the significant influence of estrogen on TAQ and VC persisted after cyclooxygenase inhibition but was eliminated after NO synthase inhibition. On the basis of the overall findings of this study, estrogenic modulation of the vascular responses to dynamic exercise appear to be mediated through PG-and NO-dependent pathways, but this occurs independent of sex.
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